InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（4 笔）
内部人交易记录
首席财务官已披露买入
0
已披露卖出
4
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the detailed record of transactions filed by Shukla Sath, 首席财务官. Director active across 1 company, notably Spero Therapeutics, Inc.. In total, 10 filings have been logged. Split: 0 buy · 4 sells. Total volume traded: €29k. Activity tracked since 26 August 2021. The latest transaction was filed on 3 February 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Shukla Sath
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报10 总计
751,407 股0Common StockSEC:0000950170-25-014850:0
2,757 股@ US$1.3511.5% 占其流量Common StockSEC:0000950170-24-101993:0
14,800 股@ US$1.3262.5% 占其流量Common StockSEC:0000950170-24-092170:0
679,501 股0Common StockSEC:0000950170-24-011487:0
1,854 股@ US$1.267.4% 占其流量Common StockSEC:0000950170-23-045441:0
266,000 股0Common StockSEC:0000950170-23-037973:0
265,957 股0Common StockSEC:0000899243-23-003945:0
6,017 股@ US$0.893818.5% 占其流量Common StockSEC:0000899243-22-030087:0
38,014 股0Common StockSEC:0000899243-22-004593:0
24,067 股0Common StockSEC:0000899243-21-034498:0
10 条申报中的 10 条
About Shukla Sath
Shukla Sath is Chief Financial Officer. He has 10 filings in total, and within the 10 sampled recent filings, the recorded transactions run from 2021-08-30 to 2025-02-05, with 0 in purchases and 28968 in sales, mainly at Spero Therapeutics, Inc. The modal transaction nature is Attribution.
